大塚ホールディングス(4578): Centanafadine承認、今後の焦点は市場浸透動向。

研报英文原文证据摘录

大塚ホールディングス(4578): Centanafadine承認、今後の焦点は市場浸透動向。

JP ٜٓ؝٤証券株式会社 ؓةؓقبنؔشؠ 株式調査部

若尾 正示AC 2026 年 7 月 27 日 J P M O R G A N

(81-3) 6736-8612

seiji.wakao@jpmorgan.com

下 ׏־ ս

Legal Entities Disclosures and Country-/Region-Specific Disclosures:

Argentina: JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina (˘BCRA˙- Central Bank of

Argentina) and Comisión Nacional de Valores (˘CNV˙- Argentinian Securities Commission - ALYC y AN Integral N°51).

Australia: J.P. Morgan Securities Australia Limited (˘JPMSAL˙) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian

Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX Clear Pty Limited

and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on behalf of JPMSAL only to

"wholesale clients" (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting

https://www.jpmm.com/research/disclosures. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base

across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of

conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate

engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been

prepared in accordance with J.P. Morgan Australia˖s Research Independence Policy which can be found at the following link: J.P. Morgan Australia -